Archives -

28
Feb

Accera Announces Results of its First Phase 3 Study in Mild-to-Moderate Alzheimer’s Disease

-Bioavailability of the drug was suboptimal- -New drug formulation addressing bioavailability has been developed and Accera is now finalizing next steps-   BOULDER, Colo., Feb. 28, 2017 — Accera, Inc., a leading CNS therapeutics company, today announced results of the AC-1204 Phase 3 study for the treatment of mild-to-moderate Alzheimer’s disease. Patients treated with AC-1204 …

30
Nov

Beyond the Failed Beta Amyloid Hypothesis

Accera’s Senior Medical Advisor, Michael Gold, M.D., to Moderate with Presentations by Russell Swerdlow, M.D., and Eugenia Trushina, Ph.D.  Boulder, Colo., Nov. 29, 2016 – Several leading Alzheimer’s disease experts will participate in a webinar hosted by Accera, Inc. at 11 a.m. EST on December 6 in advance of the 9th Annual International Conference on …

28
Nov

Interview – Accera next up in Alzheimer’s disease

By: Jonathan Gardner  Date: November 25, 2016 Lilly’s solanezumab might have blown up and erased $11bn in market capitalisation this week, but the potential reward from delivering a disease-modifying drug in Alzheimer’s disease is too attractive for many companies to ignore. Colorado-based Accera could have the next major data point in the space: readout of an early phase …

28
Nov

So long to Sola; Lilly bloom’s hope withers big pharma continues to ‘Chase’ AD dream

By Randy Osborne Last week’s phase III blowup of Eli Lilly and Co.’s solanezumab(sola) in Alzheimer’s disease (AD) struck up a familiar dirge in the failure-strewn space, and set experts to debating – again, still – the amyloid beta hypothesis, as companies that have chosen to pursue other routes continued to laud their approaches and …

26
Sep

Accera to Present at Upcoming Healthcare and Investor Conferences

Boulder, Colo., Sept. 26, 2016 – Accera, Inc., a clinical-stage biotechnology company focused on product development for Alzheimer’s disease, today announced that the company will present at the following upcoming investor conferences: 16th Annual Biotech in Europe Forum: Dr. Charles Stacey, president and CEO, will present an overview of the company on Tuesday, September 27, …

8
Sep

Accera Appoints Jeffrey Cummings and Bruno Vellas to Scientific Advisory Board

BOULDER, Colo., Sept. 8, 2016 – Accera, Inc., a clinical-stage biotechnology company focused on product development for Alzheimer’s disease, today announced the appointment of Jeffrey L. Cummings, M.D., Sc.D. and Bruno Vellas, M.D., Ph.D. to the company’s Scientific Advisory Board. “As we progress toward Phase 3 data from the NOURISH AD study later this year …

2
Aug

Accera Appoints C. Evan Ballantyne as Chief Financial Officer

BOULDER, Colo., Aug. 2, 2016 – Accera, Inc., a clinical-stage biotechnology company focused on product development for Alzheimer’s disease, today announced the appointment of C. Evan Ballantyne as chief financial officer. “Evan brings to Accera over 30 years of financial experience with a strong emphasis in healthcare and drug development in both public and private …

12
May

Accera Completes Enrollment of Phase 3 NOURISH AD Study of AC-1204 for Alzheimer’s Disease Treatment

  BOULDER, Colo., May 12, 2016 /PRNewswire/ — Accera, Inc. today announced that it has completed enrollment of the NOURISH AD Phase 3 clinical study of AC-1204 for the treatment of mild to moderate Alzheimer’s disease. The company expects to report top-line data in December. In conjunction with this, Accera is finalizing plans for a second …

5
May

Nestlé Wants to Sell You Both Sugary Snacks and Diabetes Pills

By Matthew Campbell & Corinne Gretler Nestlé is by far the largest food company in the world. Its 335,000 employees produce more than 2,000 brands, manufactured in 436 factories across 85 countries. It’s Europe’s most valuable corporation, worth $240 billion, comfortably more than oil giant Royal Dutch Shell. Among the world’s 195 nations, it sells …

27
Apr

Broomfield Biotech Firm Accera Moves to Boulder

by Joshua Lindenstein on April 27, 2016 BOULDER — Clinical-stage biotech firm Accera, which is developing a therapy to treat Alzheimer’s Disease, has moved from Broomfield to Boulder to become part of the latter’s bustling life-sciences scene and cash in Boulder’s international reputation as a startup haven. Read full article at: http://bizwest.com/broomfield-biotech-firm-accera-moves-boulder/

Page 1 of 2
X